Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors.
作者： L Sun
DOI: 10.1016/S1359-6446(00)01534-8
关键词:
摘要: Protein tyrosine kinases have emerged as crucial targets for therapeutic intervention in cancer. More recently, growth factor ligands and their respective receptor (RTKs) been shown to be required tumor cell growth. This latter aspect includes angiogenesis where the of tumors leads compensatory effects on host cells microenvironment leading microvessels. The purpose this review is focus synthetic chemical approaches block RTKs associated with a means limit spread human tumors.
elsevier.com
sci-hub.se 参考文章(66)
Israel Vlodavsky, Gerhard Christofori, Fibroblast Growth Factors in Tumor Progression and Angiogenesis Humana Press. pp. 93- 118 ,(1999) , 10.1007/978-1-59259-453-5_7
Charles J. Dimitroff, Wayne Klohs, Amarnath Sharma, Paula Pera, Denise Driscoll, Jean Veith, Randall Steinkampf, Mel Schroeder, Sylvester Klutchko, Adam Sumlin, Barbara Henderson, Thomas J. Dougherty, Ralph J. Bernacki, Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Investigational New Drugs. ,vol. 17, pp. 121- 135 ,(1999) , 10.1023/A:1006367032156
Martin Carroll, Sayuri Ohno-Jones, Shu Tamura, Elisabeth Buchdunger, Jürg Zimmermann, Nicholas B. Lydon, D. Gary Gilliland, Brian J. Druker, CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins Blood. ,vol. 90, pp. 4947- 4952 ,(1997) , 10.1182/BLOOD.V90.12.4947.4947_4947_4952
David W. Fry, Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacology & Therapeutics. ,vol. 82, pp. 207- 218 ,(1999) , 10.1016/S0163-7258(98)00050-3
Christian Sundberg, Kristofer Rubin, G Lindmark, M Ljungström, B Gerdin, Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. American Journal of Pathology. ,vol. 143, pp. 1377- 1388 ,(1993)
P. Calabresi, J. G. Beitz, A. Raymond, M. Yamamoto, J. W. Clark, J. Kato, A. R. Frackelton, N. Sato, Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. American Journal of Pathology. ,vol. 142, pp. 1119- 1130 ,(1993)
Luba Roncari, Abhijit Guha, Bodour Salhia, Gerald McMahon, Lilyana Angelov, Inhibition of Angiogenesis by Blocking Activation of the Vascular Endothelial Growth Factor Receptor 2 Leads to Decreased Growth of Neurogenic Sarcomas Cancer Research. ,vol. 59, pp. 5536- 5541 ,(1999)
David J. McConkey, Corazon D. Bucana, Wenbiao Liu, Michael R. Wilson, Darren W. Davis, Raymond M. Shaheen, Lee M. Ellis, Brian K. Zebrowski, Gerald McMahon, Antiangiogenic Therapy Targeting the Tyrosine Kinase Receptor for Vascular Endothelial Growth Factor Receptor Inhibits the Growth of Colon Cancer Liver Metastasis and Induces Tumor and Endothelial Cell Apoptosis Cancer Research. ,vol. 59, pp. 5412- 5416 ,(1999)
Walter H.J. Ward, Peter N. Cook, Anthony M. Slater, D.Huw Davies, Geoffrey A. Holdgate, Leslie R'. Green, Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochemical Pharmacology. ,vol. 48, pp. 659- 666 ,(1994) , 10.1016/0006-2952(94)90042-6
Laurent F. Hennequin, Andrew P. Thomas, Craig Johnstone, Elaine S. E. Stokes, Patrick A. Plé, Jean-Jacques M. Lohmann, Donald J. Ogilvie, Mike Dukes, Steve R. Wedge, Jon O. Curwen, Jane Kendrew, Christine Lambert-van der Brempt, Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry. ,vol. 42, pp. 5369- 5389 ,(1999) , 10.1021/JM990345W